- AREAS OF INTERESTS
- COMPANYOUR COMPANY
Targeted cancer sequencing focuses on a select set of genes, gene regions, or amplicons that are selected based on a priori knowledge. By sequencing only known cancer-relevant genes, researchers can perform sequencing more cost-effectively, with a more streamlined data analysis pipeline.
Fixed Content Sets
To facilitate targeted cancer sequencing studies, Illumina offers fixed content sets for guaranteed performance and a custom amplicon solution where researchers can choose their amplicons of interest. The table below lists key features of each targeted cancer sequencing panel.
For researchers who would prefer to customize their targeted sequencing studies, TruSeq Custom Amplicon (TSCA), enables rapid and efficient sequencing of hundreds of genomic regions covering up to 650 kb of cumulative sequence. It is amenable to a wide range of sample types, including FFPE samples. This fully integrated DNA-to-data solution includes probe design and ordering using DesignStudio, an easy-to-use online software tool that provides dynamic feedback to optimize design and region coverage.
Illumina also offers custom enrichment kits to target 0.5-25 Mb of custom content. The Nextera Custom Enrichment Kit combines the fastest workflow and customized probe design for an integrated, end-to-end custom targeted cancer exome sequencing solution.
|Panel||Catalog ID*||Cancer||Key Features||Number of Genes||Number of Amplicons||DNA Input||FFPE Compatible?|
|Solid tumors (lung, colon, melanoma, gastric and ovarian)||Dual–stranded oligo design enables highly accurate variant detection in FFPE samples||26||174||30 – 300 ng (depending on pre-run QC results)||Yes|
|TruSight Myeloid||FC-130-1010||Myeloid malignancies including MPNs** , MDS† and cancers of myeloid origin||Comprehensive myeloid panel targeting oncogenic exons and tumor suppressor genes for high throughput and accuracy||54||568||50 ng||No|
|TruSeq Amplicon Cancer Panel||FC-130-1008||Pan-cancer||Hotspot mutation panel for both solid and hematological tumors||48||212||150 ng||Yes (requires 250 ng input DNA)|
*TG-labeled consumables include features intended to help reduce the frequency of revalidation. They are available only under supply agreement and require customers to provide a binding forecast. Please contact your account manager for more information.
† Myelodysplastic Syndrome
Kenneth Bloom, MD, FCAP, Chief Medical Officer at Clarient (GE Healthcare), discusses the practical aspects of how next-generation sequencing will be applied in the clinical laboratory.
Find the Cancer Panel that best fits your needs with this easy comparison table.
Access PDF »